secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-04-11T23:59:59+00:00
Accession:  0001628280-22-008931
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Kurt Gustafson not seeking re-election at June 2022 annual meeting
---------------------------------------------------------------------------

- Gustafson notified ChromaDex on April 5, 2022 of decision.
- He will remain on Board, Audit Committee, and Compensation Committee until June 2022 meeting.
- Departure is not due to any disagreement with the Company on operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022008931/0001628280-22-008931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022008931/cdxc-20220405.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-008931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer